Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”

This article was originally published in The Tan Sheet

Executive Summary

On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.

You may also be interested in...



StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure

The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.

StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure

The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.

FTC Sets “New Normal” For Study Data Reviews, Prioritizes Health Product Claims Enforcement

At the National Advertising Division Annual Conference, FTC Chairwoman Edith Ramirez said health claims and inadequate disclosures top the agency’s priorities following settlements with advertisers in 2013 and the recent Operation Full Disclosure initiative.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel